Open access · OA
via OpenAlex
P242 Immunosuppressants can modify the transcriptomic signature in patients with systemic lupus erythematosus
Mumina Akthar, Nisha Nair, Ian N Bruce, John A. Reynolds
Lara D. Veeken · 2022
Abstract
Abstract Background/Aims Transcriptomics has the potential to revolutionise the way we approach complex diseases such as systemic lupus erythematosus (SLE), which is both clinically and biologically heterogeneous. We aimed to explore whether deconvolution of whole blood transcriptomic data could predict differences in immune cell proportions between active SLE patients, and whether these are attributable to the SLE phenotype or medication use. Methods Patients with active SLE were recruited from the BILAG-Biologics Registry (BILAG-BR) prior to change in therapy. Disease activity was measured using the BILAG-2004 Index. Whole blood RNA-sequencing was conducted at baseline and FPKM-normalised data was deconvoluted using CIBERSORTx with the LM22 signature matrix used as reference. The effects of five different drugs (azathioprine, cyclophosphamide, hydroxychloroquine, methotrexate and mycophenolate mofetil [MMF]) were explored. Predicted cell frequencies were compared between active disease domains (defined by BILAG A or B score) and concomitant immunosuppressant use using Mann-Whitney U tests with Benjamini-Hochberg correction (significance at p < 0.05). Results We recruited 109 patients of whom 104 (95.4%) were female, with a median (IQR) age of 38 years (29-49) years, disease duration of 10 (6.5, 16.5) years. Patients had active disease with a median SLEDAI score of 8 (4-14). For patients taking MMF (53/109, 46.8%), there was a lower proportion of macrophages M0 (0.435% vs 1.391%, p = 0.001), naïve CD4 T cells (0.961% vs 2.251%, p = 0.002) and regulatory T cells (1.858% vs 3.574%, p = 0.007), and a higher proportion of memory activated CD4 T cells (1.826% vs 1.113%, p = 0.015), when compared to patients not taking mycophenolate mofetil. MMF use was associated with statistically significant differences in predicted immune cell (macrophages m0, naïve CD4 T cells, regulatory T cells and memory activated CD4 T cells) frequency after adjusting for age, gender, ethnicity, disease duration, renal disease and steroid use. No differences were observed for the other immunosuppressants or between patients with active or inactive disease in each of the nine organ domains. Conclusion The use of immunosuppressants can significantly modify the transcriptomic signature in patients with SLE affecting key immune cell type populations differently, highlighting the need to adjust for background medication use in future studies, particularly in those using whole blood transcriptomics. It would also be valuable to evaluate the differences identified in this study to determine whether they can be used to monitor or predict treatment response. Disclosure M. Akthar: None. N. Nair: None. O. MASTERPLANS Consortium and BILAG BR Investigators: None. I.N. Bruce: None. J.A. Reynolds: None.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1093/rheumatology/keac133.241
- Canonical
- link ↗
- Fetched
- 2026-10-15 MST
Cite this
APA
Akthar, M., Nair, N., Bruce, I.N., & Reynolds, J.A. (2022). P242 Immunosuppressants can modify the transcriptomic signature in patients with systemic lupus erythematosus. <em>Lara D. Veeken</em>. https://doi.org/10.1093/rheumatology/keac133.241
Vancouver
Akthar M, Nair N, Bruce IN, Reynolds JA. P242 Immunosuppressants can modify the transcriptomic signature in patients with systemic lupus erythematosus. Lara D. Veeken. 2022. doi:10.1093/rheumatology/keac133.241.
BibTeX
@article{mumina2022PImmun,
title = {P242 Immunosuppressants can modify the transcriptomic signature in patients with systemic lupus erythematosus},
author = {Mumina Akthar and Nisha Nair and Ian N Bruce and John A. Reynolds},
journal = {Lara D. Veeken},
year = {2022},
doi = {10.1093/rheumatology/keac133.241},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Cells 2018
Open access · CC-BY
Pathogenic Role of Immune Cells in Rheumatoid Arthritis: Implications in Clinical Treatment and Biomarker Development
Journal of cachexia, sarcopenia and muscle 2026
Citation only
Age- and Sex-Specific Percentile Curves for the FM/FFM Ratio Using Data From the Canadian Longitudinal Study on Aging.
BMC psychiatry 2026
Open access · OA
Frailty-related vulnerability and immune cell profiles in younger adults with schizophrenia: an exploratory study.
mBio 2015
Open access · CC-BY
Epigenetics and Proteomics Join Transcriptomics in the Quest for Tuberculosis Biomarkers
Immunity & Ageing 2008
Open access · CC-BY
Immunity, ageing and cancer
Diabetes Care 2014
Open access · OA